Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: The IMAGE-HD study

Neurobiology of Disease

Volumn 51, Issue , 2013, Pages 82-92

  Georgiou Karistianis, N ^a   Gray, M A ^a,f,g   Dominguez D J F ^a   Dymowski, A R ^a   Bohanna, I ^b   Johnston, L A ^c,d   Churchyard, A ^e   Chua, P ^a   Stout, J C ^a   Egan, G F ^a,c,d  

^a MONASH UNIVERSITY   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH MEDICAL CENTRE   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Basal ganglia; Diffusion weighted imaging; Fractional anisotropy; Huntington's disease; Magnetic resonance imaging; Mean diffusivity; Multivariate classification; Quadratic discriminant function analysis; T1 weighted volume

Indexed keywords

ADULT; ARTICLE; AUTOMATION; BASAL GANGLION; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISCRIMINANT ANALYSIS; FEMALE; FRACTIONAL ANISOTROPY; GLOBUS PALLIDUS; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; THALAMUS; VOLUMETRY;

ANISOTROPY; BASAL GANGLIA; DIFFUSION MAGNETIC RESONANCE IMAGING; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; HUNTINGTON DISEASE; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 84872679179     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.10.001     Document Type: Article

References (80)

1. Albin R.L., Reiner A., Anderson K.D., Dure Iv L.S., Handelin B., Balfour R., et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 1992, 31(4):425-430.
2. Antonini A., Leenders K.L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996, 119(6):2085-2095.
3. Ashburner J., Friston K.J. Unified segmentation. NeuroImage 2005, 26(3):839-851.
4. Ashburner J., Klöppel S. Multivariate models of inter-subject anatomical variability. NeuroImage 2011, 56(2):422-439.
5. Aylward E.H., Brandt J., Codori A.M., Mangus R.S., Barta P.E., Harris G.J. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994, 44(5):823-828.
6. Aylward E.H., Codori A.M., Barta P.E., Pearlson G.D., Harris G.J., Brandt J. Basal ganglia volume and proximity to onset in preclinical Huntington's disease. Arch. Neurol. 1996, 53:1293-1296.
7. Aylward E.H., Codori A.M., Rosenblatt A., Sherr M., Brandt J., Stine O.C., et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov. Disord. 2000, 15(3):552-560.
8. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., Rosenblatt A., et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63(1):66-72.
9. Bäckman L., Robins-Wahlin T.B., Lundin A., Ginovart N., Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997, 120(12):2207-2217.
10. Beck A.T., Steer R.A., Brown G.K. Manual for the Beck Depression Inventory-II 1996, Psychological Corporation, San Antonio.
11. Bohanna I., Georgiou-Karistianis N., Egan G.F. Connectivity-based segmentation of the striatum in Huntington's disease: vulnerability of motor pathways. Neurobiol. Dis. 2011, 42(3):475-481.
12. Bohanna I., Georgiou-Karistianis N., Hannan A.J., Egan G.F. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res. Rev. 2008, 58(1):209-225.
13. Bots T., Bruyn G.W. Neuropathological changes of the nucleus accumbens in Huntington's chorea. Acta Neuropathol. 1981, 55(1):21-22.
14. Brandt J., Bylsma F.W., Aylward E.H., Rothlind J., Gow C.A. Impaired source memory in Huntington's disease and its relation to basal ganglia atrophy. J. Clin. Exp. Neuropsychol. 1995, 17(6):868-877.
15. Campodonico J.R., Aylward E., Codori A.M., Young C., Krafft L., Magdalinski M., et al. When does Huntington's disease begin?. J. Int. Neuropsychol. Soc. 1998, 4(5):467-473.
16. Chernick M.R. Bootstrap Methods: A Guide for Practitioners and Researchers 2007, John Wiley and Sons, New Jersey.
17. De la Monte S.M., Vonsattel J.P., Richardson E.P. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 1988, 47(5):516-525.
18. Della Nave R., Ginestroni A., Tessa C., Giannelli M., Piacentini S., Filippi M., Mascalchi M. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study. AJNR Am. J. Neuroradiol. 2010, 31(9):1675-1681.
19. Doty R.L., Shaman P., Kimmelman C.P., Dann M.S. University of Pennsylvania smell identification test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984, 94(2):176-178.
20. Douaud G., Behrens T.E., Poupon C., Cointepas Y., Jbabdi S., Gaura V., et al. In vivo evidence for the selective subcortical degeneration in Huntington's disease. NeuroImage 2009, 46(4):958-966.
21. Douaud G., Gaura V., Ribeiro M.J., Lethimonnier F., Maroy R., Verny C., et al. Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. NeuroImage 2006, 32(4):1562-1575.
22. Esmaeilzadeh M., Ciarmiello A., Squitieri F. Seeking brain biomarkers for preventive therapy in huntington disease. CNS Neurosci. Ther. 2011, 00:1-19.
23. Fennema-Notestine C., Archibald S.L., Jacobson M.W., Corey-Bloom J., Paulsen J.S., Peavy G.M., et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004, 63(6):989-995.
24. Georgiou-Karistianis N. A peek inside the Huntington's brain: will functional imaging take us one step closer in solving the puzzle?. Exp. Neurol. 2009, 220(1):5-8.
25. Golub G., Heath M., Wahba G. Generalized cross-validation as a method for choosing a good ridge parameter. Technometrics 1979, 21:215-224.
26. Grace J., Mallory P.F. Frontal Systems Behavior Scale: Professional Manual 2001, Psychological Assessment Resources, Lutz.
27. Harris G.J., Codori A.M., Lewis R.F., Schmidt E., Bedi A., Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999, 122(9):1667-1678.
28. Harris G.J., Pearlson G.D., Peyser C.E., Aylward E.H., Roberts J., Barta P.E., et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann. Neurol. 1992, 31(1):69-75.
29. Hastie T., Tibshirani R., Friedman J. The Elements of Statistical Learning: Data Mining, Inference and Prediction 2009, Springer. 2nd ed.
30. Henley S.M.D., Wild E.J., Hobbs N.Z., Scahill R.I., Ridgway G.R., MacManus D.G., et al. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J. Neurol. 2009, 256(2):203-212.
31. Hicks S., Rosas H.D., Berna C., Scahill R., Durmas E., Roos R.A., et al. PAW36 oculomotor deficits in presymptomatic and early Huntington's disease and their structural brain correlates. J. Neurol. Neurosurg. Psychiatry 2010, 81(11):e33.
32. Hobbs N.Z., Henley S.M., Ridgway G.R., Wild E.J., Barker R.A., Scahill R.I., Barnes J., Fox N.C., Tabrizi S.J. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J. Neurol. Neurosurg. Psychiatry 2010, 81(7):756-763.
33. Huntington Study Group Unified Huntington's disease rating scale: reliability and consistency. Mov. Disord. 1996, 11(2):136-142. (Mar).
34. Jernigan T.J., Salmon D.P., Butters N., Hesselink J.R. Cerebral structure on MRI, part ii: specific changes in Alzheimer's and Huntington's diseases. Biol. Psychiatry 1991, 29(1):68-81.
35. Jurgens C.K., Van De Wiel L., Van Es A.C.G.M., Grimbergen Y.M., Witjes-Ané M.N.W., Van Der Grond J., et al. Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease. J. Neurol. 2008, 255(11):1785-1791.
36. Kassubek J., Juengling F.D., Ecker D., Landwehrmeyer G.B. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb. Cortex 2005, 15(6):846-853.
37. Kassubek J., Juengling F.D., Kioschies T., Henkel K., Karitzky J., Kramer B., et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry 2004, 75(2):213-220.
38. Kipps C.M., Duggins A.J., Mahant N., Gomes L., Ashburner J., McCusker E.A. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J. Neurol. Neurosurg. Psychiatry 2005, 76(5):650-655.
39. Klöppel S., Chu C., Tan G.C., Draganski B., Johnson H., Paulsen J.S., et al. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology 2009, 72(5):426-431.
40. Klöppel S., Draganski B., Golding C.V., Chu C., Nagy Z., Cook P.A., et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008, 131(1):196-204.
41. Langbehn D.R., Brinkman R.R., Falush D., Paulsen J.S., Hayden M.R. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 2004, 65(4):267-277.
42. Mascalchi M., Lolli F., Della Nave R., Tessa C., Petralli R., Gavazzi C., et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology 2004, 232(3):867-873.
43. Misaki M., Kim Y., Bandettini P.A., Kriegeskorte N. Comparison of multivariate classifiers and response normalizations for pattern-information fMRI. NeuroImage 2010, 53(1):103-118.
44. Morey R.A., Selgrade E.S., Wagner H.R., Huettel S.A., Wang L., McCarthy G. Scan-rescan reliability of subcortical brain volumes derived from automated segmentation. Hum. Brain Mapp. 2010, 31(11):1751-1762.
45. Mühlau M., Gaser C., Wohlschläger A.M., Weindl A., Städtler M., Valet M., et al. Striatal gray matter loss in Huntington's disease is leftward biased. Mov. Disord. 2007, 22(8):1169-1173.
46. Nelson H.E., Willison J. National Adult Reading Test (NART) Test Manual 1991, NFER Nelson, Windsor, UK. 2nd ed.
47. Nopoulos P., Magnotta V.A., Mikos A., Paulson H., Andreasen N.C., Paulsen J.S. Morphology of the cerebral cortex in preclinical Huntington's disease. Am. J. Psychiatry 2007, 164(9):1428-1434.
48. Patenaude B., Smith S.M., Kennedy D., Jenkinson M. A Bayesian model of shape and appearance for subcortical brain. NeuroImage 2011, 56(3):907-922.
49. Paulsen J.S. Functional imaging in Huntington's disease. Exp. Neurol. 2009, 216(2):272-277.
50. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross C.A., Nance M., et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 2008, 79(8):874-880.
51. Paulsen J.S., Magnotta V.A., Mikos A.E., Paulson H.L., Penziner E., Andreasen N.C., et al. Brain structure in preclinical Huntington's disease. Biol. Psychiatry 2006, 59(1):57-63.
52. Peinemann A., Schuller S., Pohl C., Jahn T., Weindl A., Kassubek J. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J. Neurol. Sci. 2005, 239(1):11-19.
53. Pereira F., Mitchell T., Botvinick M. Machine learning and fMRI: a tutorial overview. NeuroImage 2009, 45(Suppl. 1):S199-S209.
54. Reading S.A.J., Yassa M.A., Bakker A., Dziorny A.C., Gourley L.M., Yallapragada V., et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res. 2005, 140(1):55-62.
55. Rizk-Jackson A., Stoffers D., Sheldon S., Kuperman J., Dale A., Goldstein J., et al. Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques. NeuroImage 2011, 56(2):788-796.
56. Rosas H.D., Goodman J., Chen Y.I., Jenkins B.G., Kennedy D.N., Makris N., et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001, 57(6):1025-1028.
57. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60(10):1615-1620. (May 27).
58. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58(5):695-701. (Mar 12).
59. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131(Pt 4):1057-1068. (Apr).
60. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov. Disord. 2006, 21(9):1317-1325.
61. Ruocco H.H., Lopes-Cendes I., Li L.M., Santos-Silva M., Cendes F. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Braz. J. Med. Biol. Res. 2006, 39(8):1129-1136.
62. Sánchez-Castañeda, C., Cherubini, A., Elifani, F., Péran, P., Orobello, S., Capelli, G., Sabatini, U., Squitieri, F., in press. Seeking Huntington disease biomarkers by multi-modal, cross-sectional basal ganglia imaging. Hum. Brain Mapp.
63. Seppi K., Schocke M.F.H., Mair K.J., Esterhammer R., Weirich-Schwaiger H., Utermann B., et al. Diffusion-weighted imaging in Huntington's disease. Mov. Disord. 2006, 21(7):1043-1047.
64. Smith A. Symbol Digit Modality Test (SDMT): Manual (Revised) 1982, Psychological Services, Los Angeles.
65. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E., Johansen-Berg H., et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23(Suppl. 1):S208-S219.
66. Soneson C., Fontes M., Zhou Y., Denisov V., Paulsen J.S., Kirik D., et al. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol. Dis. 2010, 40(3):531-543.
67. Sritharan A., Egan G.F., Johnston L., Horne M., Bradshaw J.L., Bohanna I., et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2010, 81(3):257-262.
68. Starkstein S.E., Brandt J., Bylsma F., Peyser C., Folstein M., Folstein S.E. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study. Neuroradiology 1992, 34(6):487-489.
69. Steyerberg E.W. Clinical Prediction Models: A Practical Approach to development, Validation, and Updating 2009, Springer.
70. Stoffers D., Sheldon S., Kuperman J.M., Goldstein J., Corey-Bloom J., Aron A.R. Contrasting gray and white matter changes in preclinical Huntington disease: An MRI study. Neurology 2010, 7(15):1208-1216.
71. Stout J.C., Paulsen J.S., Queller S., Solomon A.C., Whitlock K.B., Campbell J.C., et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011, 25(1):1-14.
72. Stroop J.R. Studies of interference in serial verbal reactions. J. Exp. Psychol. 1935, 18(6):643-662.
73. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8(9):791-801. (Sep).
74. Thieben M.J., Duggins A.J., Good C.D., Gomes L., Mahant N., Richards F., et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002, 125(8):1815-1828.
75. Tinslet H.E.A., Brown S.D. Multivariate statistics and mathematical modelling. Handbook of Applied Multivariate Statistics and Mathematical Modelling 2000, Academic Press, California. H. Tinslet, S. Brown (Eds.).
76. van den Bogaard S.J.A., Dumas E.M., Acharya T.P., Johnson H., Langbehn D.R., Scahill R.I., et al. Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J. Neurol. 2010, 1-9.
77. van der Schaaf, A., Xu, C.-J, van Luijk, P, van't Veld, A.A, Langendijk, J.A, Schilstra, C., in press. Multivariate modeling of complications with data driven variable selection: Guarding against overfitting and effects of data set size. Radiother. Oncol.
78. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44(6):559-577. (Nov).
79. Watson D., Wu K.D. Development and validation of the schedule of compulsions, obsessions, and pathological impulses (SCOPI). Assessment 2005, 12(1):50-65.
80. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67(6):361-370.